Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
The Methodist Hospital Research Institute
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
Aveni Foundation
Dana-Farber Cancer Institute
Kaiser Permanente
Duke University
University of Florida
Essen Biotech
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
Unity Health Toronto
Institut Bergonié
University of Nebraska
Imperial College London
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Mayo Clinic
City of Hope Medical Center
City of Hope Medical Center
University Health Network, Toronto
Cancer Research UK
University of Southern California
Hospices Civils de Lyon
Georgetown University
Memorial Sloan Kettering Cancer Center
Maastricht University Medical Center
Sahlgrenska University Hospital
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Cancer Research UK
University of Virginia
Institut Bergonié
University of Alabama at Birmingham
Zhejiang University
University of Alberta
Memorial Sloan Kettering Cancer Center
Stanford University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
Stanford University
Universidade Federal de Pernambuco
University of Toronto
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
Stanford University